Apollo Endosurgery Inc (NASDAQ:APEN) major shareholder Stonepine Capital, L.P. bought 22,845 shares of the company’s stock in a transaction on Wednesday, January 3rd. The shares were bought at an average price of $5.71 per share, with a total value of $130,444.95. Following the completion of the transaction, the insider now owns 2,560,314 shares of the company’s stock, valued at $14,619,392.94. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Major shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Stonepine Capital, L.P. also recently made the following trade(s):

  • On Saturday, December 29th, Stonepine Capital, L.P. bought 5,163 shares of Apollo Endosurgery stock. The shares were bought at an average price of $5.56 per share, with a total value of $28,706.28.
  • On Tuesday, December 26th, Stonepine Capital, L.P. bought 5,287 shares of Apollo Endosurgery stock. The shares were bought at an average price of $5.00 per share, with a total value of $26,435.00.
  • On Wednesday, December 20th, Stonepine Capital, L.P. bought 45,434 shares of Apollo Endosurgery stock. The shares were bought at an average price of $4.50 per share, with a total value of $204,453.00.
  • On Friday, December 22nd, Stonepine Capital, L.P. bought 185,157 shares of Apollo Endosurgery stock. The shares were bought at an average price of $4.85 per share, with a total value of $898,011.45.

Shares of Apollo Endosurgery Inc (NASDAQ APEN) traded down $0.07 on Thursday, hitting $5.82. 66,700 shares of the stock were exchanged, compared to its average volume of 76,200. The company has a market cap of $102.53, a price-to-earnings ratio of -0.27 and a beta of 0.44. The company has a current ratio of 2.54, a quick ratio of 2.00 and a debt-to-equity ratio of 0.58. Apollo Endosurgery Inc has a 1 year low of $3.55 and a 1 year high of $19.95.

APEN has been the subject of several research analyst reports. Northland Securities reiterated a “buy” rating and set a $12.00 target price on shares of Apollo Endosurgery in a research report on Tuesday, November 28th. Zacks Investment Research upgraded shares of Apollo Endosurgery from a “hold” rating to a “buy” rating and set a $4.75 target price for the company in a research report on Thursday, November 2nd. ValuEngine upgraded shares of Apollo Endosurgery from a “strong sell” rating to a “sell” rating in a research report on Wednesday. Finally, Roth Capital set a $10.00 target price on shares of Apollo Endosurgery and gave the company a “buy” rating in a research report on Thursday. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $9.44.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Stonepine Capital Management LLC bought a new stake in shares of Apollo Endosurgery in the 3rd quarter worth approximately $11,067,000. King Luther Capital Management Corp bought a new stake in shares of Apollo Endosurgery in the 3rd quarter worth approximately $2,567,000. Russell Investments Group Ltd. bought a new stake in shares of Apollo Endosurgery in the 3rd quarter worth approximately $1,288,000. Woodmont Investment Counsel LLC bought a new stake in shares of Apollo Endosurgery in the 3rd quarter worth approximately $220,000. Finally, JPMorgan Chase & Co. bought a new stake in shares of Apollo Endosurgery in the 3rd quarter worth approximately $119,000. Hedge funds and other institutional investors own 23.67% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece of content on another domain, it was stolen and republished in violation of international trademark and copyright laws. The original version of this piece of content can be accessed at https://www.thecerbatgem.com/2018/01/04/apollo-endosurgery-inc-apen-major-shareholder-stonepine-capital-l-p-purchases-22845-shares.html.

Apollo Endosurgery Company Profile

Apollo Endosurgery, Inc, formerly Lpath, Inc, is a medical device company. The Company is focused on less invasive therapies for the treatment of obesity, as well as other gastrointestinal disorders. The Company’s device-based therapies are an alternative to invasive surgical procedures. The Company offers products in over 80 countries.

Insider Buying and Selling by Quarter for Apollo Endosurgery (NASDAQ:APEN)

Receive News & Stock Ratings for Apollo Endosurgery Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apollo Endosurgery and related stocks with our FREE daily email newsletter.